Introduction The development of targeted radionuclide therapy using therapeutic radiopharmaceuticals has quickly emerged as an accurate and efficient delivery of radiation directly to tumor cells. One of the main benefits of radiopharmaceutical drug delivery is the ability to target diseased cells whilst sparing healthy surrounding tissue. This transformative class of pharmaceuticals has seen a rapid increase in research and development over the last decade and more, with sponsors investing in next-generation radioligand therapy (RLT) programs...










